Vera Therapeutics

Vera Therapeutics

Yahoo Finance • 6 days ago

Vera Therapeutics Wins FDA Accelerated Approval For TRUTAKNA In Primary IgA Nephropathy

(RTTNews) - Vera Therapeutics, (VERA), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted TRUTAKNA (atacicept-vymj) accelerated approval to reduce proteinuria in adults with primary... Full story

Yahoo Finance • 7 days ago

Vera gains after FDA nod for kidney disease therapy

[FDA Headquarters] * Shares of Vera Therapeutics (VERA [https://seekingalpha.com/symbol/VERA]) jumped on Tuesday after the U.S. Food and Drug Administration approved the company’s kidney disease therapy, atacicept, under its accelerated... Full story

Yahoo Finance • 7 days ago

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).1,2The TRUTAKNA dose... Full story

Yahoo Finance • 8 days ago

Scilex, Vera Therapeutics rise premarket; Strategy gains

Investing.com - U.S. stock index futures edged higher on Monday as investors returned from a long holiday weekend, with technology shares leading gains. By 07:47 ET, the Dow futures contract was little changed, S&P 500 futures had risen b... Full story

Yahoo Finance • 11 days ago

Catalyst Watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings

[Headquarters of SpaceX in Hawthorne, California] Sven Piper Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next wee... Full story

Yahoo Finance • 27 days ago

Vera Therapeutics (VERA) Appears Attractive After Latest FDA Agreement

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the 10 best mid-cap stocks that could double your money. On June 2, Vera Therapeutics, Inc. (NASDAQ:VERA) announced that it reached an agreement with the U.S. Food and Drug Administration reg... Full story

Yahoo Finance • last month

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted... Full story

Yahoo Finance • 2 months ago

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

DelveInsight Business Research LLP The IgAN market is growing due to rising prevalence, improved diagnostics, novel immunotherapies, ongoing clinical trials of therapies such as Zigakibart (Novartis), Sefaxersen (F. Hoffmann-La Roche/Ioni... Full story

Yahoo Finance • 3 months ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Quick Read The GLP-1 wave has triggered a broader biopharma M&A cycle extending well beyond obesity drugs. These five biotech companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline... Full story

Yahoo Finance • 4 months ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, to... Full story

Yahoo Finance • 4 months ago

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SE... Full story

Yahoo Finance • 4 months ago

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,... Full story

Yahoo Finance • 4 months ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • 4 months ago

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish

Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric... Full story

Yahoo Finance • 4 months ago

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment

Key Points Eversept Partners added 264,468 shares of Vera Therapeutics in the fourth quarter; the estimated transaction value was $9.39 million based on quarterly average pricing. Meanwhile, the quarter-end position value increased in val... Full story

Yahoo Finance • 4 months ago

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Key Points Deerfield Management Company bought 418,538 Vera Therapeutics shares in the fourth quarter; the estimated trade size was $14.87 million. Meanwhile, the quarter-end position value rose by $99.77 million, reflecting both the new... Full story

Yahoo Finance • 4 months ago

Vera Therapeutics Appoints Christopher Hite to Board of Directors

BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, to... Full story

Yahoo Finance • 5 months ago

Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)

Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside. On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estima... Full story

Yahoo Finance • 7 months ago

Vera Therapeutics prices public offering to raise $261M at $42.50 a share

Vera Therapeutics (VERA [https://seekingalpha.com/symbol/VERA]) announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20334494-vera-therapeutics-announces-pricing-of-public-offering-of-class-a-common-stock]... Full story

Yahoo Finance • 7 months ago

Vera Therapeutics announces $200M public offering

* Vera Therapeutics (NVSDAQ:ERA) stated [https://seekingalpha.com/pr/20332409-vera-therapeutics-announces-proposed-public-offering-of-class-a-common-stock] on Monday that it had commenced a public offering to issue and sell $200M of shar... Full story